Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
作者： Pierre Laurent-Puig , Anne Cayre , Gilles Manceau , Emmanuel Buc , Jean-Baptiste Bachet
关键词:
摘要: Purpose The occurrence of KRAS mutation is predictive nonresponse and shorter survival in patients treated by anti–epidermal growth factor receptor (anti-EGFR) antibody for metastatic colorectal cancer (mCRC), leading the European Medicine Agency to limit its use with wild-type tumors. However, only half these will benefit from treatment, suggesting need identify additional biomarkers cetuximab-based treatment efficacy. Patients Methods We retrospectively collected tumors 173 mCRC. All but one patient received a regimen as second-line or greater therapy. BRAF status were assessed allelic discrimination. EGFR amplification was chromogenic situ hybridization fluorescent hybridization, expression PTEN immunochemistry. Results In (n = 116), mutations 5) weakly associated lack response (P .063) s...
archives-ouvertes.fr
sci-hub.se 
researchgate.net 参考文章(39)
Nicola Personeni, Steffen Fieuws, Hubert Piessevaux, Gert De Hertogh, Jef De Schutter, Bart Biesmans, Wendy De Roock, An Capoen, Maria Debiec-Rychter, Jean-Luc Van Laethem, Marc Peeters, Yves Humblet, Eric Van Cutsem, Sabine Tejpar, Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab : A fluorescent in situ hybridization study Clinical Cancer Research. ,vol. 14, pp. 5869- 5876 ,(2008) , 10.1158/1078-0432.CCR-08-0449
F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685
Katrien Berns, Hugo M. Horlings, Bryan T. Hennessy, Mandy Madiredjo, E. Marielle Hijmans, Karin Beelen, Sabine C. Linn, Ana Maria Gonzalez-Angulo, Katherine Stemke-Hale, Michael Hauptmann, Roderick L. Beijersbergen, Gordon B. Mills, Marc J. van de Vijver, René Bernards, A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. ,vol. 12, pp. 395- 402 ,(2007) , 10.1016/J.CCR.2007.08.030
Najah T Nassif, Glenn P Lobo, Xiaojuan Wu, Christopher JA Henderson, Carl D Morrison, Charis Eng, Bin Jalaludin, Eva Segelov, PTEN mutations are common in sporadic microsatellite stable colorectal cancer Oncogene. ,vol. 23, pp. 617- 628 ,(2004) , 10.1038/SJ.ONC.1207059
Ludovic Barault, Nicolas Veyrie, Valerie Jooste, Delphine Lecorre, Caroline Chapusot, Jean-Marc Ferraz, Astrid Lièvre, Marion Cortet, Anne-Marie Bouvier, Patrick Rat, Patrick Roignot, Jean Faivre, Pierre Laurent-Puig, Francoise Piard, Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers International Journal of Cancer. ,vol. 122, pp. 2255- 2259 ,(2008) , 10.1002/IJC.23388
Antoine Italiano, Philippe Follana, François-Xavier Caroli, Jean-Luc Badetti, Daniel Benchimol, Georges Garnier, Jean Gugenheim, Juliette Haudebourg, Frédérique Keslair, Gérard Lesbats, Gérard Lledo, Jean-Francois Roussel, Florence Pedeutour, Eric François, Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors for Which FISH Analysis Does Not Detect an Increase in EGFR Gene Copy Number Annals of Surgical Oncology. ,vol. 15, pp. 649- 654 ,(2008) , 10.1245/S10434-007-9667-2
Yoichi Nagata, Keng-Hsueh Lan, Xiaoyan Zhou, Ming Tan, Francisco J. Esteva, Aysegul A. Sahin, Kristine S. Klos, Ping Li, Brett P. Monia, Nina T. Nguyen, Gabriel N. Hortobagyi, Mien-Chie Hung, Dihua Yu, PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell. ,vol. 6, pp. 117- 127 ,(2004) , 10.1016/J.CCR.2004.06.022
Ingo K Mellinghoff, Maria Y Wang, Igor Vivanco, Daphne A Haas-Kogan, Shaojun Zhu, Ederlyn Q Dia, Kan V Lu, Koji Yoshimoto, Julie HY Huang, Dennis J Chute, Bridget L Riggs, Steve Horvath, Linda M Liau, Webster K Cavenee, P Nagesh Rao, Rameen Beroukhim, Timothy C Peck, Jeffrey C Lee, William R Sellers, David Stokoe, Michael Prados, Timothy F Cloughesy, Charles L Sawyers, Paul S Mischel, None, Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England Journal of Medicine. ,vol. 353, pp. 2012- 2024 ,(2005) , 10.1056/NEJMOA051918
Minaxi Jhawer, Sanjay Goel, Andrew J. Wilson, Cristina Montagna, Yi-He Ling, Do-Sun Byun, Shannon Nasser, Diego Arango, Joongho Shin, Lidija Klampfer, Leonard H. Augenlicht, Roman Perez Soler, John M. Mariadason, PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab Cancer Research. ,vol. 68, pp. 1953- 1961 ,(2008) , 10.1158/0008-5472.CAN-07-5659
Isabelle Sansal, William R. Sellers, The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway Journal of Clinical Oncology. ,vol. 22, pp. 2954- 2963 ,(2004) , 10.1200/JCO.2004.02.141